Oncolytics Biotech Aktie [WKN DE: A2JMW5 / ISIN: CA6823108759]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen
Ausblick

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen
Ausblick

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Oncolytics Biotech Inc Registered Shs

12.04.21		Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study (PR Newswire)
12.04.21		Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study (PR Newswire)
12.04.21		Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study (PR Newswire)
12.04.21		Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting (PR Newswire)
12.04.21		Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting (PR Newswire)
12.04.21		Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting (PR Newswire)
08.04.21		Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference (PR Newswire)
08.04.21		Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference (PR Newswire)
08.04.21		Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference (PR Newswire)
05.04.21		Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid... (PR Newswire)
05.04.21		Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid... (PR Newswire)
05.04.21		Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid... (PR Newswire)
10.03.21		Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting (PR Newswire)
10.03.21		Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting (PR Newswire)
10.03.21		Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting (PR Newswire)
05.03.21		Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (PR Newswire)
05.03.21		Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (PR Newswire)
05.03.21		Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (PR Newswire)
26.02.21		Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights (PR Newswire)
26.02.21		Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights (PR Newswire)
26.02.21		Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights (PR Newswire)
23.02.21		Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors (PR Newswire)
23.02.21		Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors (PR Newswire)
23.02.21		Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors (PR Newswire)
09.12.20		Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
09.12.20		Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
09.12.20		Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
19.11.20		Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
19.11.20		Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
19.11.20		Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
17.11.20		Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
17.11.20		Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
17.11.20		Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium (PR Newswire)
11.11.20		Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results (PR Newswire)
11.11.20		Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results (PR Newswire)
11.11.20		Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results (PR Newswire)
09.11.20		Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
09.11.20		Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting (PR Newswire)
27.10.20		Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor (PR Newswire)
27.10.20		Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor (PR Newswire)
27.10.20		Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor (PR Newswire)
07.10.20		Oncolytics Biotech® to Participate in BIO Investor Forum Digital (PR Newswire)
07.10.20		Oncolytics Biotech® to Participate in BIO Investor Forum Digital (PR Newswire)
07.10.20		Oncolytics Biotech® to Participate in BIO Investor Forum Digital (PR Newswire)
29.05.20		At The ASCO: ONCY, IMV, CRDF, GILD, TAK… (RTTNews)
09.01.20		Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

OMV-Aktie gefragt: Deutsche Bank erhöht Kursziel - "Handelsblatt"-Journalist wird Kommunikationschef

US-Börsen beenden Sitzung in Grün -- ATX geht wenig bewegt aus dem Handel -- DAX schließt fester -- Märkte in Fernost geben letztlich ab

Übernahmefantasie treibt HUGO BOSS-Aktie bis zum Handelsschluss kräftig an - Gerry Weber-Aktien ziehen mit

Tesla in China unter Druck: Entschuldigung nach Protest auf Automesse - Tesla-Aktie fester

Daimler schickt wegen Chipkrise Tausende Mitarbeiter in Kurzarbeit - Daimler-Aktie klar im Minus

Fed im Fokus: Welche Gefahren bringt die Inflation aktuell mit sich?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Wie bewerten Sie diese Seite?

schlecht sehr gut

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2021 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

** Hinweis zu Plus500: 76,4% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:
Kaufwert:	EUR
	Hinzufügen Speichern

Oncolytics Biotech Aktie [WKN DE: A2JMW5 / ISIN: CA6823108759]

Nachrichten zu Oncolytics Biotech Inc Registered Shs

Eintrag hinzufügen Eintrag bearbeiten

Newssuche

Meistgelesene Nachrichten